Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection
- PMID: 28391418
- DOI: 10.1007/s10620-017-4564-4
Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection
Abstract
Background: The eradication of Helicobacter pylori infection remains a challenge, especially in the patients unsuitable to take penicillin. Cephalosporin has the potential to replace amoxicillin for H. pylori eradication.
Aims: To compare the effectiveness, safety, and compliance of amoxicillin- and cefuroxime-containing quadruple regimens in treatment-naïve patients.
Methods: In this open-label randomized control study, 400 patients with H. pylori infection were divided into amoxicillin-containing (esomeprazole 20 mg twice/day, amoxicillin 1000 mg twice/day, levofloxacin 500 mg once/day, and bismuth 220 mg twice/day for 14 days) or cefuroxime-containing (esomeprazole 20 mg twice/day, cefuroxime 500 mg twice/day, levofloxacin 500 mg once/day, and bismuth 220 mg twice/day for 14 days) quadruple therapy groups. The safety and compliance were assessed 1-3 days after eradication. Urea breath test was performed 8-12 weeks after eradication to determine treatment outcome.
Results: The baseline data including antibiotic resistance were well matched between the two groups. The eradication rates between amoxicillin- and cefuroxime-containing quadruple therapy groups were not significantly different [intention-to-treat analysis: 83.5% (95% confidence interval 78.3-88.7%) vs. 81.0% (75.5-86.5%), P = 0.513; modified intention-to-treat analysis: 90.3% (86.0-94.6%) vs. 88.5% (83.9-93.2%), P = 0.586; per-protocol analysis: 91.6% (87.5-95.7%) vs. 89.8% (85.3-94.3%), P = 0.560]. The incidence of adverse effects (18.4 vs. 20.1%, P = 0.678) and compliance (94.7 vs. 94.2%, P = 0.813) were also similar. Variate analyses showed that antibiotic resistance and poor compliance were the independent risk factors for eradication failure.
Conclusions: Esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime achieved similar and relatively satisfactory cure rates, safety, and compliance in first-line H. pylori eradication. Cefuroxime may be a good alternative medicine for eradication instead of amoxicillin for the patients unsuitable to take penicillin.
Keywords: Amoxicillin; Cefuroxime; Compliance; Eradication; Helicobacter pylori; Safety.
Similar articles
-
Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.BMC Gastroenterol. 2019 Jul 25;19(1):132. doi: 10.1186/s12876-019-1056-3. BMC Gastroenterol. 2019. PMID: 31345165 Free PMC article.
-
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.Dig Liver Dis. 2016 May;48(5):506-511. doi: 10.1016/j.dld.2016.01.002. Epub 2016 Jan 15. Dig Liver Dis. 2016. PMID: 26847964
-
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.Aliment Pharmacol Ther. 2015 Apr;41(8):768-75. doi: 10.1111/apt.13128. Epub 2015 Feb 23. Aliment Pharmacol Ther. 2015. PMID: 25703120 Clinical Trial.
-
Second-line rescue treatment of Helicobacter pylori infection: Where are we now?World J Gastroenterol. 2018 Oct 28;24(40):4548-4553. doi: 10.3748/wjg.v24.i40.4548. World J Gastroenterol. 2018. PMID: 30386104 Free PMC article. Review.
-
Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: A review article.Helicobacter. 2024 Mar-Apr;29(2):e13073. doi: 10.1111/hel.13073. Helicobacter. 2024. PMID: 38601987
Cited by
-
Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.BMC Gastroenterol. 2019 Jul 25;19(1):132. doi: 10.1186/s12876-019-1056-3. BMC Gastroenterol. 2019. PMID: 31345165 Free PMC article.
-
A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime.Ther Adv Drug Saf. 2024 Jun 13;15:20420986241258049. doi: 10.1177/20420986241258049. eCollection 2024. Ther Adv Drug Saf. 2024. PMID: 38881538 Free PMC article.
-
Antibiotic resistance profile of Helicobacter pylori to 14 antibiotics: a multicenter study in Fujian, China.PeerJ. 2023 Jul 11;11:e15611. doi: 10.7717/peerj.15611. eCollection 2023. PeerJ. 2023. PMID: 37456872 Free PMC article.
-
Randomized multicenter trial comparing minocycline and ornidazole with classical quadruple therapy in Helicobacter pylori treatment.Sci Rep. 2025 May 10;15(1):16318. doi: 10.1038/s41598-025-01117-9. Sci Rep. 2025. PMID: 40348820 Free PMC article. Clinical Trial.
-
Primary Antibiotic Resistance of Helicobacter pylori in Different Regions of China: A Systematic Review and Meta-Analysis.Pathogens. 2022 Jul 12;11(7):786. doi: 10.3390/pathogens11070786. Pathogens. 2022. PMID: 35890031 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical